Discover if this is a suitable investor for your startup. If they are we'll make a warm introduction for free. Otherwise, we'll connect you with matching investors.
Amplitude Ventures is a venture capital firm founded in 2026 and based in Canada, dedicated to creating, building, and growing precision medicine companies that enhance patient outcomes. With a fund size of $192 million, Amplitude Ventures operates under a full-stack model, providing not only capital but also active participation in the development of its portfolio companies. The firm has established a strong reputation in the biotech and healthcare sectors, particularly in North America, with offices located in Montreal, Toronto, and Calgary. Co-founded by Jean-Francois Pariseau and Dion Madsen, both of whom have extensive backgrounds in venture capital, Amplitude Ventures has quickly positioned itself as a leader in precision medicine investment. The firm focuses on therapeutic areas such as cardiology, drug discovery, immunology, metabolic diseases, neurology, neurovascular conditions, oncology, and rare diseases. Their commitment to improving patient outcomes through innovative diagnostics and treatments sets them apart in the competitive venture capital landscape.
Amplitude Ventures invests in companies that operate at the intersection of biology and machine learning, with a keen interest in precision medicine. The firm targets therapeutic areas including cardiology, drug discovery, immunology, metabolic diseases, neurology, neurovascular conditions, oncology, and rare diseases. Their investment strategy encompasses seed, Series A, and Series B stages, allowing them to engage with companies at various points in their development. Amplitude Ventures seeks to partner with founders who are passionate about leveraging technology to enhance patient outcomes. The firm is particularly interested in innovative diagnostics and treatments that can significantly impact healthcare delivery. By focusing on the integration of AI and biology, Amplitude Ventures aims to support companies that are pioneering advancements in precision medicine, thereby addressing unmet medical needs and improving patient care.
Amplitude Ventures boasts a diverse portfolio of notable investments in the biotech and healthcare sectors. Key portfolio companies include **Congruence**, which specializes in AI-powered protein folding platforms, and **Evommune**, which develops treatments for moderate-to-severe atopic dermatitis. The firm has also supported **Radiant Biotherapeutics**, helping them scale effectively, and co-led a $76 million Series B financing for **Mediar Therapeutics**. Other significant investments include **Celsius Therapeutics**, which received ongoing support throughout its growth, **Ability Biotherapeutics**, where Amplitude was the first investor and played a crucial role in strategic development, and **Abdera Therapeutics**, which has benefited from Amplitude's support from early stages through various financing rounds. This robust portfolio reflects Amplitude Ventures' commitment to fostering innovation in precision medicine and its ability to identify and nurture high-potential companies.
Jean-Francois Pariseau: Co-founder of Amplitude Ventures, Jean-Francois has a strong background in venture capital and has previously worked with BDC Capital. He focuses on identifying and supporting innovative companies in the biotech sector.
Dion Madsen: Co-founder and partner at Amplitude Ventures, Dion brings extensive experience in venture capital and a passion for precision medicine, helping to guide the firm's investment strategy.
Founders interested in pitching Amplitude Ventures should reach out via email at info@amplitudevc.com. The firm is open to both warm introductions and cold applications, and pitches should clearly outline the innovative aspects of the company and its alignment with Amplitude's focus on precision medicine.
Amplitude Ventures has been actively involved in financing and supporting various biotech companies. Recent activities include co-leading a $76 million Series B financing for Mediar Therapeutics and providing strategic development support to several portfolio companies. The firm continues to deploy its second fund, focusing on precision medicine investments.
All trademarks, logos and brand names are the property of their respective owners. All company, product and service names used in this website are for identification purposes only. Use of these names, trademarks, and brands does not imply endorsement.